title: A sensitive solid-phase fluoroimmunoassay for detection of opiates in urine.
abstract: An automated flow fluorometer designed for kinetic binding analysis was adapted to develop a solid-phase competitive fluoroimmunoassay for urinalysis of opiates. The solid phase consisted of polymer beads coated with commercial monoclonal antibodies (MAbs) raised against morphine. Fluorescein-conjugated morphine (FL-MOR) was used as the fluorescein-labeled hapten. The dissociation equilibrium constant (K(D)) for the binding of FL-MOR to the anti-MOR MAb was 0.23 nM. The binding of FL-MOR to the anti-MOR MAb reached steady state within minutes and was displaced effectively by morphine and other opiates. Morphine-3-glucuronide (M3G), the major urinary metabolite of heroin and morphine, competed effectively with FL-MOR in a concentration-dependent manner for binding to the antimorphine MAb and was therefore used to construct the calibration curve. The sensitivity of the assay was 0.2 ng/mL for M3G. The assay was effective at concentrations of M3G from 0.2 to 50 ng/mL, with an IC50 of 2 ng/mL. Other opiates and heroin metabolites that showed >50% crossreactivity when present at 1 microg/mL included codeine, morphine-6-glucuronide, and oxycodone. Methadone showed very low crossreactivity (<5%), which is a benefit for testing in patients being treated for opiate addictions. The high sensitivity of the assay and the relatively high cutoff value for positive opiate tests allows very small sample volumes (e.g., in saliva or sweat) to be analyzed. A double-blind comparison using 205 clinical urine samples showed good agreement between this single-step competitive assay and a commercially performed enzyme multiplied immunoassay technique for the detection of opiates and benzoylecgonine (a metabolite of cocaine).
authors.affiliation: Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore 21201, USA. melde001@umaryland.edu
authors.forename: M E
authors.initials: ME
authors.lastname: Eldefrawi
authors.forename: N L
authors.initials: NL
authors.lastname: Azer
authors.forename: N
authors.initials: N
authors.lastname: Nath
authors.forename: N A
authors.initials: NA
authors.lastname: Anis
authors.forename: M S
authors.initials: MS
authors.lastname: Bangalore
authors.forename: K P
authors.initials: KP
authors.lastname: O'Connell
authors.forename: R P
authors.initials: RP
authors.lastname: Schwartz
authors.forename: J
authors.initials: J
authors.lastname: Wright
mesh_terms: D000911:Antibodies, Monoclonal; D001322:Autoanalysis; D001667:Binding, Competitive; D003061:Codeine / Q000652:urine; D019793:Fluorescein; D015200:Fluoroimmunoassay / Q000379:methods*; D006801:Humans; D008863:Microspheres; D009020:Morphine / Q000276:immunology; D009022:Morphine Derivatives / Q000652:urine; D009294:Narcotics / Q000652:urine*; D010098:Oxycodone / Q000652:urine; D012680:Sensitivity and Specificity
chemical_list: D000911:Antibodies, Monoclonal; D009022:Morphine Derivatives; D009294:Narcotics; C035349:morphine-6-glucuronide; D009020:Morphine; D010098:Oxycodone; D019793:Fluorescein; D003061:Codeine